NEW
YORK, Nov. 15, 2023 /PRNewswire/ --
Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or
"Delcath"), an interventional oncology company focused
on the treatment of primary and metastatic cancers of the liver,
announces that the Company granted equity awards, previously
approved by the Company's Compensation Committee, as a material
inducement to the employment of five individuals.
The grant totaled the right to purchase an aggregate of
69,000 shares of the Company's common stock, outside of the
Company's Omnibus 2020 Equity Incentive Plan, as amended ("Plan").
The grant date of the options is the date the Compensation
Committee approved the stock options included within the equity
inducement, and the options have an exercise price equal to the
closing price of Delcath common stock on the grant date
with ten-year terms. One-third of the options will vest on
the first anniversary of the grant date with the remaining
two-thirds of the options vesting in equal monthly installments
over the following twenty-four months. The vesting of the options
is subject to the employee's continued employment with Delcath on
each vesting date.
The above-described awards were each granted in accordance with
NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the
terms of the Plan.
About Delcath Systems, Inc.
Delcath Systems,
Inc. is an interventional oncology company focused on
the treatment of primary and metastatic liver cancers. The
Company's proprietary products, HEPZATO KITâ„¢
(melphalan for Injection/Hepatic Delivery System),
approved for use in the United
States by the Food and Drug Administration, and
CHEMOSAT Hepatic Delivery System for Melphalan
percutaneous hepatic perfusion (PHP), designated
under the medical device regulation for use in Europe and the United Kingdom, are designed to administer
high-dose chemotherapy to the liver while controlling systemic
exposure and associated side effects during a PHP
procedure. For more information regarding HEPZATO
KIT and its use, including Important Safety Information and
Boxed Warning, please visit HEPZATOKIT.com. For more
information regarding CHEMOSAT and its use,
please visit Chemosat.com.
Contact:
Investor Relations Contact:
Ben
Shamsian Lytham Partners
646-829-9701
shamsian@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/delcath-systems-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301989684.html
SOURCE Delcath Systems, Inc.